VIR BIOTECHNOLOGY, INC.

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$1.4M

Filings

Firms Hired

Active Period

2020–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	$510,000	12	3
2022	$600,000	12	3
2021	$290,000	11	3
2020	—	6	2

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
VIR BIOTECHNOLOGY, INC.	$1,400,000	11
FORBES-TATE	—	27
W STRATEGIES, LLC	—	14

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	48
SENATE	42
Health & Human Services, Dept of (HHS)	35
Centers For Medicare and Medicaid Services (CMS)	10
Office of Science & Technology Policy (OSTP)	10
Natl Institutes of Health (NIH)	9
Centers For Disease Control & Prevention (CDC)	4
Natl Security Council (NSC)	4
U.S. International Trade Commission (ITC)	4
White House Office	4

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	52
Government Issues	Government Issues	20
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	18
Budget/Appropriations	Budget/Appropriations	13
Medicare/Medicaid	Medicare/Medicaid	12
Science/Technology	Science/Technology	11
Trade (domestic/foreign)	Trade (domestic/foreign)	4

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 2673118th Congress

American Innovation and R&D Competitiveness Act of 2023

2023 · fourth_quarter · Firm: W STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.

Client expense: — · Firm income: $30,000

Matched citations: H.R.2673

H.R. 2673118th Congress

American Innovation and R&D Competitiveness Act of 2023

2023 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 2673

H.R. 3938118th Congress

Build It in America Act

2023 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 3938

S. 476118th Congress

Maintaining Investments in New Innovation Act

2023 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Inflation Reduction Act Rx Provisions Implementation; S. 476, Maintaining Investments in New Innovation Act

Client expense: $70,000 · Firm income: —

Matched citations: S. 476

Show 21 more cited filings

S. 866118th Congress

American Innovation and Jobs Act

2023 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $70,000 · Firm income: —

Matched citations: S. 866

H.R. 2673118th Congress

American Innovation and R&D Competitiveness Act of 2023

2023 · third_quarter · Firm: W STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.

Client expense: — · Firm income: $50,000

Matched citations: H.R.2673

H.R. 2673118th Congress

American Innovation and R&D Competitiveness Act of 2023

2023 · third_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $140,000 · Firm income: —

Matched citations: H.R. 2673

H.R. 3938118th Congress

Build It in America Act

2023 · third_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $140,000 · Firm income: —

Matched citations: H.R. 3938

S. 476118th Congress

Maintaining Investments in New Innovation Act

2023 · third_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

Inflation Reduction Act Rx Provisions Implementation; S. 476, Maintaining Investments in New Innovation Act

Client expense: $140,000 · Firm income: —

Matched citations: S. 476

S. 866118th Congress

American Innovation and Jobs Act

2023 · third_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $140,000 · Firm income: —

Matched citations: S. 866

H.R. 2673118th Congress

American Innovation and R&D Competitiveness Act of 2023

2023 · second_quarter · Firm: W STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.2673 - American Innovation and R&D Competitiveness Act of 2023.

Client expense: — · Firm income: $50,000

Matched citations: H.R.2673

H.R. 2673118th Congress

American Innovation and R&D Competitiveness Act of 2023

2023 · second_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $160,000 · Firm income: —

Matched citations: H.R. 2673

H.R. 3938118th Congress

Build It in America Act

2023 · second_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $160,000 · Firm income: —

Matched citations: H.R. 3938

S. 866118th Congress

American Innovation and Jobs Act

2023 · second_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act; H.R. 2673, American Innovation and R&D Competitiveness Act; H.R. 3938, Build It In America Act

Client expense: $160,000 · Firm income: —

Matched citations: S. 866

S. 866118th Congress

American Innovation and Jobs Act

2023 · first_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 866, American Innovation and Jobs Act

Client expense: $140,000 · Firm income: —

Matched citations: S. 866

H.R. 1304117th Congress

American Innovation and R&D Competitiveness Act of 2021

2022 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing; H.R. 1304, American Innovation and R&D Competitiveness Act

Client expense: $140,000 · Firm income: —

Matched citations: H.R. 1304

H.R. 2617117th Congress

Consolidated Appropriations Act, 2023

2022 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; H.R. 2617, Consolidated Appropriations Act for FY 2023

Client expense: $140,000 · Firm income: —

Matched citations: H.R. 2617

H.R. 6025117th Congress

Flu Vaccine Act

2022 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; H.R. 2617, Consolidated Appropriations Act for FY 2023

Client expense: $140,000 · Firm income: —

Matched citations: H.R. 6025

H.R. 7410117th Congress

American Made Medicine Act

2022 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing; H.R. 1304, American Innovation and R&D Competitiveness Act

Client expense: $140,000 · Firm income: —

Matched citations: H.R. 7410

H.R. 7505117th Congress

To amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities.

2022 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing; H.R. 1304, American Innovation and R&D Competitiveness Act

Client expense: $140,000 · Firm income: —

Matched citations: H.R. 7505

S. 2640117th Congress

Disease X Act

2022 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; H.R. 2617, Consolidated Appropriations Act for FY 2023

Client expense: $140,000 · Firm income: —

Matched citations: S. 2640

S. 3258117th Congress

Flu Vaccine Act

2022 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; H.R. 2617, Consolidated Appropriations Act for FY 2023

Client expense: $140,000 · Firm income: —

Matched citations: S. 3258

S. 3799117th Congress

PREVENT Pandemics Act

2022 · fourth_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; H.R. 2617, Consolidated Appropriations Act for FY 2023

Client expense: $140,000 · Firm income: —

Matched citations: S. 3799

H.R. 1304117th Congress

American Innovation and R&D Competitiveness Act of 2021

2022 · fourth_quarter · Firm: W STRATEGIES, LLC

Open original LDA filing ↗

Cited source text and reported amounts

H.R.1304 - American Innovation and R&D Competitiveness Act of 2021.

Client expense: — · Firm income: $50,000

Matched citations: H.R.1304

H.R. 1304117th Congress

American Innovation and R&D Competitiveness Act of 2021

2022 · third_quarter · Firm: VIR BIOTECHNOLOGY, INC.

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing; H.R. 1304, American Innovation and R&D Competitiveness Act

Client expense: $150,000 · Firm income: —

Matched citations: H.R. 1304

Source: Senate LDA

VIR BIOTECHNOLOGY, INC. — Lobbying Disclosure | Poliscope